ストックスクリーナーアプリを入手
16.64
0.24%
0.04
アフターアワーズ：
16.41
-0.23
-1.38%
Theravance Biopharma Inc (TBPH) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages Theravance Biopharma, Inc. (TBPH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 - MSN
2026-04-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Investors to Learn More About the Investigation | NDAQ:TBPH | Press Release - Stockhouse
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewir - The National Law Review
Risk Report: Is Theravance Biopharma Inc a cyclical or defensive stockPortfolio Return Summary & Verified Chart Pattern Signals - baoquankhu1.vn
2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Stockholders to Reach Out | NDAQ:TBPH | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire
Theravance's Q4 earnings and revenues miss estimates - MSN
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH) - The Globe and Mail
TBPH: B. Riley Securities Raises Price Target to $17.00, Maintai - GuruFocus
B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating - marketscreener.com
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH - marketbeat.com
Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares - Stock Titan
Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4 - Stock Titan
Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant - Stock Titan
Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing - Stock Titan
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
TBPH PE Ratio & Valuation, Is TBPH Overvalued - Intellectia AI
How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing - Stock Traders Daily
Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Big Picture: Can Theravance Biopharma Inc sustain its profitabilityLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement - TipRanks
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. - Bitget
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement - Stock Titan
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Theravance Biopharma SEC Filing: Exhibits, Documents, and XBRL Taxonomy Reference Table - Minichart
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan
Theravance drops rare disease drug after late-stage trial setback - MSN
Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus
TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada
Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - tradingview.com
Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan
Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN
(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):